EGFR and non-small cell lung carcinoma: Moreover, W2014-S had a synergistic effect with the EGFR-TKI gefitinib on NSCLC PDX models that have acquired resistance to EGFR-TKIs.195 The IDH mutation has been an essential target for AML, which blocks AML cells’ differentiation.